Technology Bundle ID: TAB-2698

Nucleic Acid Detection of the Fungal Pathogen Histoplasma capsulatum from Clinical and Environmental Samples

Request More Info
Licensing Contact:
Primary Inventors: 
Millie Schafer (CDC)
Co-Inventors: 
Thomas Reid (CDC)
Development Stage: 
Pre-Clinical (in vitro)
Development Status: 

In vitro data available

Institute or Center: 
CDC

This invention relates to detecting Histoplasma capsulatum by PCR using oligonucleotide probes specific for the fungus. Histoplasmosis is a mycotic infection of varying severity, usually localized in the lungs. Caused by H. capsulatum, infections are usually symptomatic but can develop into chronic disease, especially in immunocompromised individuals.

Test samples may originate from the environment (soil, for example), where H. capsulatum spores are found or from clinical samples obtained from patients. Furthermore, the invention also provides for methods that detect the presence of H. capsulatum in a sample using a nested, or two-stage, PCR assay.

Applications:
  • Directing antifungal drug therapy for improved patient outcomes
  • Occupational health and safety screening for workers who may encounter bird or bat waste
  • Screening biological or soil samples for the presence of fungal pathogens
  • Environment testing for immunocompromised patients
Advantages:
  • Rapid and precise
  • Cost-effective
  • Easily adapted for H. capsulatum detection kits
  • Can positively identify small sample sizes of as few as 10 spores
  • High-throughput capable

Patents

PCT Application PCT/US1999/008731
Filed on 1999-04-20
US Application 60/082,477
Filed on 1998-04-21
US Pat 6,469,156

Issued 2002-10-22

Publications

Reid TM, Schafer MP.
PMID 10441199

Updated

Dec 23, 2013

Data Source: 
tts